Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 1;32(9):738-743.
doi: 10.1097/IJG.0000000000002271. Epub 2023 Jul 20.

Short-Term Outcomes of Bimatoprost Sustained-Release Intracameral Implant in Glaucoma

Michael K Wong  1 , Mallory E Bowers  1 , Jonas Ventimiglia  2 , Rachel M Niknam  3 , Marlene R Moster  3 , Michael J Pro  3 , Elizabeth Dale  3 , Natasha N Kolomeyer  3 , Daniel Lee  3 , Cindy X Zheng  3
Affiliations

Short-Term Outcomes of Bimatoprost Sustained-Release Intracameral Implant in Glaucoma

Michael K Wong et al. J Glaucoma. .

Abstract

Prcis: This retrospective study found a statistically significant reduction in mean intraocular pressure (IOP) and the number of medications after intracameral Bimatoprost sustained release (SR) injection in patients with glaucoma. A history of selective laser trabeculoplasty (SLT) did not impact treatment outcomes.

Purpose: To determine outcomes of Bimatoprost SR on IOP and the number of topical IOP-lowering medications in patients with glaucoma. A secondary objective was to determine the outcomes of Bimatoprost SR in patients with a prior history of SLT.

Methods: Retrospective case series. One hundred eighteen eyes from 84 patients that received Bimatoprost SR by 6 glaucoma specialists at Wills Eye Hospital from March 2020 to September 2021 were examined. The intervention was a single injection of intracameral Bimatoprost SR. The main outcome measures included IOP and the number of medications.

Results: The most recent mean follow-up time for all eyes was 27.8 ± 18.6 weeks. The mean posttreatment IOP at the most recent follow-up of 16.6 ± 5.3 mm Hg was significantly lower than the mean under-therapy pretreatment IOP of 18.5 ± 5.7 mm Hg for all eyes ( P < 0.01). The mean posttreatment number of medications at the most recent follow-up of 1.3 ± 1.3 decreased compared with the number of pretreatment medications of 2.1 ± 1.4 for all eyes ( P < 0.01). Analysis of multilevel models controlling for demographic variables demonstrated a statistically significant reduction in IOP and number of medications posttreatment ( P < 0.01). A prior history of SLT (n = 54) had no impact on treatment for both IOP and the number of medications ( P > 0.1 for both).

Conclusions: Intracameral Bimatoprost SR reduced IOP and decreased the number of medications. Prior history of SLT did not impact Bimatoprost SR treatment outcomes.

PubMed Disclaimer

Conflict of interest statement

Disclosure: R.M.N.: Allergan/Abbvie. M.R.M.: Allergan, Glaukos, Bausch and Lomb, Alcon, Nicox, Santen, Qura. M.J.P.: New World Medical. N.N.K.: Abbvie/Allergan, Guardion Health Services Inc, Equinox, Nicox, Olleyes, Santen, Glaukos, Diopsys, Aerie, Regeneron, Alimera, Genetech. D.L.: Allergan, Glaukos, New World Medical, Ocular Therapeutix, Olleyes, Equinox, Mati, Nicox, Santen. The remaining authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844–851.
    1. Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol. 2012;96:614–618.
    1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–267.
    1. GBD 2019. Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9:e144–e160.
    1. American Academy of Ophthalmology. Primary open angle glaucoma preferred practice pattern; November 2020. Accessed December 20, 2022. https://www.aao.org/preferred-practice-pattern/primary-open-angle-glauco...